Articles From: BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study in OPMD to BioDelivery Sciences Announces the Availability of BUNAVAIL™ in the U.S.


Interim Data on First 11 Patients in the Ongoing Phase 2/3 HOPEMD Study Suggest Cabaletta to be Safe and Well Tolerated with No Drug Related Adverse Events TEL AVIV, Israel, Sept.
Sign-up for BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study in OPMD investment picks
TEL AVIV, Israel, Aug.
Sign-up for BioBlast Pharma Reports Second Quarter Financial Results investment picks
TEL AVIV, Israel, Sept.
Sign-up for BioBlast to Ring the NASDAQ Stock Market Opening Bell investment picks
SAN DIEGO and PRINCETON, N.J. and REHOVOT, Israel, Oct.
Sign-up for Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells investment picks
SAN DIEGO, Dec.
Sign-up for Biocept Appoints Experienced Physician as Medical Director investment picks
SAN DIEGO, Oct.
Sign-up for Biocept Expands Collaboration With MD Anderson Cancer Center investment picks
SAN DIEGO, Nov.
Sign-up for Biocept Launches Lung Cancer Offering investment picks
SAN DIEGO, Nov.
Sign-up for Biocept Reports Third Quarter 2014 Financial Results investment picks
SAN DIEGO, Sept.
Sign-up for Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe investment picks
SAN DIEGO, Sept.
Sign-up for Biocept to Present at the 13th Annual BIO Investor Forum investment picks
SAN DIEGO, Sept.
Sign-up for Biocept to Present at Upcoming Investor Conferences investment picks
BANGALORE, India and MONMOUTH JUNCTION, N.J. , Nov.
Sign-up for Biocon Expands its Strategic Partnership with CytoSorbents for CytoSorb® to Treat SIRS and Cardiac Surgery Patients investment picks
RESEARCH TRIANGLE PARK, N.C., Oct.
Sign-up for BioCryst Announces Late Breaker Presentation of OPuS-1 Phase 2 Trial Results at the 23rd EADV Congress investment picks
RESEARCH TRIANGLE PARK, N.C., Sept.
Sign-up for BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting investment picks
RESEARCH TRIANGLE PARK, N.C., Sept.
Sign-up for BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies investment picks
RESEARCH TRIANGLE PARK, N.C., Sept.
Sign-up for BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases investment picks
RESEARCH TRIANGLE PARK, N.C., Aug.
Sign-up for BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate Study of BCX4430 in Ebola Virus Disease investment picks
RESEARCH TRIANGLE PARK, N.C., Nov.
Sign-up for BioCryst Reports Third Quarter 2014 Financial Results investment picks
RESEARCH TRIANGLE PARK, N.C., Oct.
Sign-up for BioCryst to Announce Third Quarter 2014 Financial Results November 6 investment picks
RESEARCH TRIANGLE PARK, N.C., Sept.
Sign-up for BioCryst to Present at Rodman & Renshaw Conference investment picks
RESEARCH TRIANGLE PARK, N.C., Nov.
Sign-up for BioCryst to Present at Two Upcoming Investor Conferences investment picks
RESEARCH TRIANGLE PARK, N.C., Sept.
Sign-up for BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G027887-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/12/4/11G027887/Biodel-Life-Delivered_000-1401197537254.jpg DANBURY, CT--(Marketwired - December 04, 2014) - Biodel Inc. (NASDAQ: BIOD) today announced that the company has initiated enrollment of normal human subjects in a Phase 1 clinical trial of its lyophilized glucagon formulation designed for use in a proprietary auto-reconstitution device intended for the rescue of patients with severe hypoglycemia.
Sign-up for Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G026660-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/11/17/11G026660/Biodel-Life-Delivered_000-1401197537254.jpg DANBURY, CT--(Marketwired - November 18, 2014) - Biodel Inc. (NASDAQ: BIOD) announced that it has successfully defended oppositions to two of its granted European patents for its ultra-rapid-acting insulin formulations, EP 2 319 500 and EP 2 106 790.
Sign-up for Biodel Successfully Defends Ultra-Rapid-Acting Insulin Formulation Technology in European Patent Office Opposition Proceedings investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G028288-001&sourceType=1 DANBURY, CT--(Marketwired - December 10, 2014) - Biodel Inc. (NASDAQ: BIOD) will issue its fourth quarter fiscal year 2014 financial results on Wednesday, December 17, 2014.
Sign-up for Biodel to Report Fourth Quarter Fiscal Year 2014 Financial Results on December 17, 2014 investment picks
Top line data anticipated by end of first quarter 2015 RALEIGH, N.C. , Dec.
Sign-up for BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy investment picks
BUNAVAIL Is the First and Only Buccal Film Formulation of Buprenorphine and Naloxone for the Maintenance Treatment of Opioid Dependence BUNAVAIL Shipped to Wholesalers; Pharmacy Availability Anticipated by End of This Week RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences Announces the Availability of BUNAVAIL™ in the U.S. investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: BioBlast Pharma Announces Preclinical and Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study in OPMD to BioDelivery Sciences Announces the Availability of BUNAVAIL™ in the U.S.
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent